Tomohiko Adachi

Tomohiko Adachi

Auto-generated profile, based on publicly available information

Tomohiko Adachi

Department of Surgery Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2021 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
PDF file
TATomohiko Adachi
Tomohiko Adachi
SESusumu Eguchi
Susumu Eguchi
YMYoshihiro Mutoh
Yoshihiro Mutoh

11 September 2013 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
PDF file
TATomohiko Adachi
Tomohiko Adachi
Susumu EguchiSusumu Eguchi
Susumu Eguchi

1 July 2015 in Pancreatology
Verified
Journal Article
Open access
TATomohiko Adachi
Tomohiko Adachi
TKTamotsu Kuroki
Tamotsu Kuroki
AKAmane Kitasato
Amane Kitasato
MHMasataka Hirabaru
Masataka Hirabaru
HMHajime Matsushima
Hajime Matsushima
Susumu EguchiSusumu Eguchi
Susumu Eguchi
Postoperative management after DP with early drain removal and TDT was safe and effective for preventing PF.

16 September 2022 in Surgery
Verified
Journal Article
Closed access
SOShinichiro Ono
Shinichiro Ono
TATomohiko Adachi
Tomohiko Adachi
TOTakao Ohtsuka
Takao Ohtsuka
RKRyuichiro Kimura
Ryuichiro Kimura
KNKazuyoshi Nishihara
Kazuyoshi Nishihara
Susumu EguchiSusumu Eguchi
Susumu Eguchi

27 April 2019 in Trials
Verified
Journal Article
Open access
PDF file
MKMasahiro Katsuda
Masahiro Katsuda
MMMotoki Miyazawa
Motoki Miyazawa
Toshiyasu OjimaToshiyasu Ojima
Toshiyasu Ojima
AKAkio Katanuma
Akio Katanuma
KHKenichi Hakamada
Kenichi Hakamada
HYHiroki Yamaue
Hiroki Yamaue
Pancreatic cancer is a refractory malignancy, and the development of a new effective treatment strategy is needed. We generated a dendritic cell vaccine by culturing monocytes obtained by apheresis of blood from each patient, inducing their differentiation into dendritic cells, and pulsing with tumor antigen peptides. However, the clinical efficacy of the vaccine has not been established. We therefore decided to conduct an exploratory clinical trial of dendritic cell vaccine loaded with Wilms’ tumor gene 1 peptides (TLP0-001) as a potential new treatment for patients with advanced pancreatic cancer refractory to standard chemotherapy. This is an investigator-initiated, double-blind, comparative trial. The patients were allocated to two groups in a 1:1 ratio through a central registration by dynamic allocation. A total of 185 patients with inoperable or metastatic pancreatic cancer who were refractory or intolerant to standard primary chemotherapy with gemcitabine plus nab-paclitaxel will be allocated to secondary treatment either with placebo in combination with S-1 (the control group) or TLP0-001 in combination with S-1 (the investigational product group). The primary objective of this trial is to evaluate the safety and efficacy (as measured by overall survival) of the investigational product by comparing the two groups. This clinical trial will be performed in accordance with Japanese Good Clinical Practice guidelines. Clinical trials of the standard regimen, including gemcitabine, for advanced pancreatic cancer are ongoing worldwide. However, a strategy for after the primary treatment has not been established. We therefore decided to conduct this study to evaluate the safety and efficacy of TLP0-001 as a secondary treatment for pancreatic cancer in anticipation of the approval of this new drug in Japan. This trial is conducted with full consideration of safety, as it is the first-in-human clinical trial of TLP0-001; thus, the trial will be conducted only at the Second Department of Surgery at Wakayama Medical University until the safety is confirmed by interim analysis. We plan to conduct a multicenter trial at 18 institutions in Japan after confirmation of the safety. University Hospital Medical Information Network Clinical Trials Registry, UMIN000027179 . Registered on 9 April 2017.

3 April 2021 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
YHYu Huang
Yu Huang
YSYusuke Sakai
Yusuke Sakai
THTakanobu Hara
Takanobu Hara
TKTakeshi Katsuda
Takeshi Katsuda
TOTakahiro Ochiya
Takahiro Ochiya
Susumu EguchiSusumu Eguchi
Susumu Eguchi